Sign in
Subscribe
    • Stock Lists
      arrow_drop_down
      • Longevity Stocks
      • COVID-19 Stocks
    • Longevity Trial Tracker
    • Newsletter
    • Resources
      arrow_drop_down
      • Events
      • Supporters
    • About
    Subscribe

    Gensight Biologics (SIGHT.PA)

    gene therapy for severe degenerative diseases of the eye and central nervous system

    • Profile
    • prev
    • next
    • Bookmark
    • Website
    • Share
    • prev
    • next
    $SIGHT.PA
    3,46 €
    0,0400 €
    1.11%

    Marketcap: 159,72 €M
    Volume: 30,74 K

    GENSIGHT BIOLOGICS
    Symbol: SIGHT.PA
    Employees: 44
    GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
    Website https://www.gensight-biologics.com

    LongevityMarketcap.com 2021.

      • Facebook
      • Twitter
      • WhatsApp
      • Telegram
      • LinkedIn
      • Tumblr
      • VKontakte
      • Mail
      • Copy link